Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 3/20 | 0.41 |
| ▸ | RARG | P13631 | 3/20 | 0.41 |
| ▸ | RARA | P10276 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 6/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10158656 | 0.84 | NOTUM (0.47) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL2243072 | 0.83 | CYP26A1 (0.48) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL506223 | 0.83 | NOTUM (0.46) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL13318332 | 0.83 | NOTUM (0.46) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL3550976 | 0.83 | RARB (0.47) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL18656430 | 0.80 | NOTUM (0.43) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL5658006 | 0.80 | BACE1 (0.45) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL5782492 | 0.80 | RARB (0.45) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL13547946 | 0.80 | PTGS2 (0.44) | NOTUMPTGS1PTGS2RARBRARG | |
| SCHEMBL5780794 | 0.80 | PTGS2 (0.44) | NOTUMPTGS1PTGS2RARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2061760-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | NOTUM 637/4885PTGS1 1026/4885PTGS2 777/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | NOTUM 1197/4885PTGS1 1289/4885PTGS2 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.